Treating OSD in 2024

Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, MBA, MS, FAAO, kick off 2024 with a conversation about several new and anticipated products for treating ocular surface disease, including cyclosporine ophthalmic solution 0.1% (Vevye, Harrow), perfluorohexyloctane ophthalmic solution (Meibo, Bausch + Lomb), and lotilaner ophthalmic solution 0.25% (Xdemvy, Tarsus Pharmaceuticals). They also share some practice pearls and professional goals for the year ahead.